Navigation Links
New study shows TGen spin-off boosts Scottsdale economy
Date:1/21/2010

SCOTTSDALE, Ariz. Jan. 21, 2010 TGen Drug Development (TD2) is poised to play a significant role in the expansion of Scottsdale's biomedical industry, fostering new jobs and city revenues, and prompting the creation of more related businesses.

That is the conclusion of a new report released today by the independent economic research firm Tripp Umbach of Pittsburgh about TD2's economic impact on Scottsdale.

And while TD2's contributions to Scottsdale already are solid, its projected impact within 5 years will increase by nearly tenfold, the Tripp Umbach report concludes.

TD2's direct annual economic impact on Scottsdale in 2009 was $4.3 million. But when TD2's affiliated company operations are included, the total economic impact in 2009 was pegged by Tripp Umbach at more than $26 million. That total economic impact is projected to reach more than $239 million by 2015, the report said.

"Working alongside other key biomedical engines like the Mayo Clinic and Scottsdale Healthcare, TD2 holds the promise of a brighter economic future for Scottsdale, and the promise of better healthcare for all Arizonans," said Dr. Stephen Gately, TD2's President and Chief Scientific Officer.

Other economic impacts and projections for TD2 identified by Tripp Umbach include:

  • Total employment generated directly and indirectly from TD2's Scottsdale operations and affiliated companies equaled at least 106 jobs. By 2015 the number of jobs generated by TD2 and affiliated companies should reach 1,080.

  • Operations of TD2 and affiliated companies in 2009 generated more than $729,000 in city revenues. In 2010, TD2 and affiliated companies will have generated more cumulative tax revenues than the dollars initially invested by Scottsdale. By 2015, annual city revenues generated by TD2 and affiliated companies should reach nearly $6.6 million.

  • By 2015, Scottsdale should see an economic return of $7.89 for every $1 invested in TD2.

TD2 is a non-profit, whole-owned subsidiary of the Phoenix-based, non-profit Translational Genomics Research Institute (TGen). A recent Tripp Umbach report showed that TGen's annual economic impact on Arizona in 2009 was more than $77 million.

TD2 was created in 2003 as a way of commercializing the research discoveries of TGen. Scottsdale provided a $3 million loan to accelerate TD2's growth. TD2 was the first non-Mayo business partner welcomed by the Mayo Clinic Scottsdale to its biomedical campus at 134th Street and Shea Boulevard.

Its mission is to facilitate drug development and move new compounds to patients as quickly as possible. TD2 provides a comprehensive program of pre-clinical, clinical and regulatory services to ensure expeditious approval by the U.S. Food and Drug Administration of treatments that are proved to be safe and effective.

In part because of TD2, many related businesses have located in Scottsdale: Ascalon International Inc., MCS Biotech Resources LLC, Semafore Pharmaceuticals Inc., Silamed Inc., Stromaceutics Inc., SynDevRx Inc., and Translational Accelerator LLC (TRAC).


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Herpes medication does not reduce risk of HIV transmission, UW-led international study finds
2. Mouse Study May Advance Multiple Sclerosis Research
3. Employer Satisfaction With Health Insurers Is Declining, Finds PricewaterhouseCoopers Study
4. Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study
5. Study Questions Need for Emergency Appendectomies
6. Treatment for chronic hepatitis C: A phase II study
7. Zambian study finds longer breastfeeding best for HIV-infected mothers
8. Refinement of glaucoma testing, treatment expected from US, United Kingdom study
9. McGill-CHUM study: 56 percent of young adults in a new sexual relationship infected with HPV
10. Synomics Pharma and Bioscience Laboratories Announce Partnership to Provide Topical Clinical Phase 1 Study Services
11. Study Shows Pine Bark Naturally Relieves Symptoms of Acute Hemorrhoids
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... ... May 22, 2017 , ... Patients who avoid necessary dental ... sedation dentistry in Mt. Kisco, NY from Advanced Endodontics of Westchester. This highly-trained team ... of treatments. One or more sedation methods may be recommended based on the severity ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... “Homeostasis: The ... experience learning to live with Bipolar 1. Donald Rodriguez takes readers on a rollercoaster ... Alaska in the dead of winter and to a dark place where Donald considers ...
(Date:5/22/2017)... IL (PRWEB) , ... May 22, 2017 , ... ... is part of a larger group investing in InsightRX, an early stage company ... patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund acted ...
(Date:5/21/2017)... ... May 20, 2017 , ... Pixel Film Studios presents ... use in Final Cut Pro X. The business-oriented elements and dignified animations are ... ProParagraph Corporate will deliver a professional and distinguished look to any multi-line text ...
(Date:5/21/2017)... ... May 21, 2017 , ... For more than 20 ... a wide range of knives and swords, from functional to fantasy. United Cutlery has ... with sleek, modern designs that defy tradition. , Offering a range of weapons and ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... BURNIE, Md. , May 10, 2017 ... retention solutions for the clinical research industry, is proud ... www.CSSiEnroll.com . The new website features both enriched ... overall user experience and enhances the company,s already well-established ... the industry. "After many months of ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its commitment ... of directors for the Pharmaceutical Research and Manufacturers ... membership. Biopharmaceutical companies will now have to meet ... to be eligible to join PhRMA. ... board is sending a clear message that being ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, ... provides technology solutions to improve the clinical effectiveness ... results for the first quarter ended March 31, ... products enable our customers to identify when preventive ... intervene before events like heart attacks or strokes ...
Breaking Medicine Technology: